Health Economics›Endometrial cancer›Non-endocrine therapy for advanced recurrent or metastatic disease

Non-endocrine therapy for advanced recurrent or metastatic disease

Endometrial cancer · 30 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin and Paclitaxel (CP), Olaparib, Durvalumab Variant #01	—	R 291 501	28d	15.1 mo	—	17	R 4 955 516 PFS proxy	1
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~5.8 mo	~15.5 mo	~13	~R 3 730 419 PFS proxy · indirect	40
Carboplatin and Paclitaxel (CP) and Pembrolizumab Variant #03	—	R 248 201	42d	13.1 mo	—	10	R 2 482 011 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Durvalumab Variant #01	—	R 232 277	28d	10.2 mo	—	12	R 2 787 323 PFS proxy	1
Lenvatinib and Pembrolizumab Variant #01	—	R 128 546	21d	—	18.3 mo	—	—	1
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	~20.4 mo	~51.6 mo	~30	~R 1 717 393 PFS proxy · indirect	3
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #12	—	R 45 174	21d	8.1 mo	22.8 mo	12	R 542 091 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Atezolizumab Variant #01	—	R 33 699	21d	10.1 mo	—	15	R 505 487 PFS proxy	1
Carboplatin and Paclitaxel (CP), Bevacizumab, Cadonilimab Variant #01 Partial	—	R 30 657	21d	12.7 mo	—	19	R 582 492 PFS proxy	2
Cisplatin and Paclitaxel (TP), Bevacizumab, Cadonilimab Variant #01 Partial	—	R 30 087	21d	12.7 mo	—	19	R 571 654 PFS proxy	2
Cisplatin and Paclitaxel (TP) and Bevacizumab Variant #01	—	R 29 810	21d	8.1 mo	22.8 mo	12	R 357 715 PFS proxy	2
Dactinomycin monotherapy Variant #01	—	R 18 019	28d	—	—	—	—	—
Carboplatin and Pegylated liposomal doxorubicin Variant #01	—	R 14 626	28d	~10.7 mo	~21.4 mo	~12	~R 175 507 PFS proxy · indirect	5
Carboplatin and Paclitaxel (CP) and Trastuzumab Variant #02	—	R 12 882	21d	12.9 mo	—	19	R 244 759 PFS proxy	1
Cisplatin and Ifosfamide Variant #01	—	R 12 083	21d	6.0 mo	—	9	R 108 747 PFS proxy	1
Topotecan monotherapy Variant #01	—	R 11 563	21d	~4.6 mo	~12.7 mo	~7	~R 80 942 PFS proxy · indirect	13
Ifosfamide monotherapy N/A - secondary systemic drug	—	R 9 835	28d	4.0 mo	8.4 mo	5	R 49 173 PFS proxy	2
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	8.8 mo	29.4 mo	13	R 65 399 PFS proxy	11
Cisplatin and Doxorubicin N/A - secondary systemic drug	—	R 3 077	21d	5.7 mo	12.3 mo	9	R 27 693 PFS proxy	2
Carboplatin and Paclitaxel (CP) and Dostarlimab Variant #01 Partial	—	R 2 239	42d	—	44.6 mo	—	—	2
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	—	11.9 mo	—	—	2
Carboplatin and Paclitaxel (CP) and Cadonilimab Variant #01 Partial	—	R 2 034	21d	12.7 mo	—	19	R 38 651 PFS proxy	2
Cisplatin, Doxorubicin, Paclitaxel Variant #01	—	R 1 791	21d	—	28.2 mo	—	—	2
Cisplatin and Paclitaxel (TP) and Cadonilimab Variant #01 Partial	—	R 1 464	21d	12.7 mo	—	19	R 27 813 PFS proxy	2
Ifosfamide and Paclitaxel N/A - secondary systemic drug	—	R 1 375	21d	—	21.3 mo	—	—	2
Doxorubicin monotherapy Variant #10	—	R 1 293	21d	3.8 mo	9.2 mo	6	R 7 759 PFS proxy	2
Carboplatin monotherapy Variant #01	—	R 1 231	21d	~5.8 mo	~21.0 mo	~9	~R 11 076 PFS proxy · indirect	7
Cisplatin and Paclitaxel (TP) Variant #01	—	R 716	10d	8.1 mo	22.8 mo	25	R 17 905 PFS proxy	2
Temsirolimus monotherapy N/A - secondary systemic drug	—	R 0	28d	~4.8 mo	~17.2 mo	~6	~R 1 PFS proxy · indirect	3
Dostarlimab monotherapy Variant #01 Partial	—	—	42d	—	—	—	—	—

30 of 30 regimens shown